This editorial refers to 'Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice' by K.R. McGaffin et al., pp. 60-71, this issue.
As a consequence of advances in invasive and pharmacological treatment, significantly more patients survive an acute myocardial infarction and enter the chronic phase of infarct healing. Unfortunately, their convalescence is complicated by the development of adverse myocardial remodelling, a pathophysiological condition characterized by dilation and increased sphericity of the infarcted ventricle and by hypertrophy of the non-infarcted myocardium. Post-infarction remodelling is a strong predictor of mortality and arrhythmias and leads to the development of heart failure. 1 The pathogenesis of remodelling in the infarcted heart is intertwined with the responses involved in cardiac repair. Loss of cardiomyocytes following infarction initiates an inflammatory reaction that leads to clearance of the wound from dead cells and debris, but also activates pro-apoptotic and matrixdegrading pathways that may exacerbate injury and enhance chamber dilation. Mobilization of fibroblasts provides the cellular substrate necessary to form a supportive scar, but also results in matrix deposition and active interstitial remodelling in the perimysium of the viable myocardium, increasing dysfunction. Deposition and crosslinking of collagen worsens diastolic function, whereas loss of endogenous matrix-derived survival signals, due to active turnover of extracellular matrix proteins and persistent inflammation, may result in cardiomyocyte apoptosis, precipitating further decline in systolic function of the ventricle. 2 Beyond their established role in regulation of appetite and metabolism, adipokines have also been implicated in cardiac pathophysiology and in regulation of myocardial injury, inflammation, and repair. In the myocardium, leptin signals through short (Ob-Ra) and long (Ob-Rb) isoforms of the leptin receptor, shown to be closely related to the class I cytokine receptor family. Leptin binding causes conformational changes and triggers reciprocal autophosphorylation of two Janus kinase (JAK) molecules that are associated with the proline-rich cytoplasmic region of leptin receptor. Activated JAK phosphorylates tyrosine residues (Tyr985, Tyr1077, and Tyr1138) of the receptor, providing docking sites for signal transducer and activator of transcription (STAT) proteins that subsequently become tyrosinephosphorylated by JAK. Phosphorylated STAT molecules dimerize and translocate to the nucleus to activate transcription of target genes. In addition, leptin activates STAT-independent pathways like extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3 ′ -kinase cascades. Evidence suggests that expression of leptin and its receptor is increased in experimental models of myocardial infarction and in the failing human heart. However, because leptin is capable of modulating phenotype and function of all cells associated with cardiac injury and repair, its role in the healing infarct remains poorly understood. Global leptin deficiency results in impaired cardiac structure and function following myocardial infarction. On the other hand, treatment with an anti-leptin neutralizing antibody was shown to mitigate dysfunction following infarction, and exogenous administration of high doses of leptin in infarcted mice resulted in accentuated adverse remodelling. 3 Thus, published experimental evidence suggests that leptin may exert both cardioprotective and detrimental effects on the injured heart ( Figure 1) . McGaffin et al. 4 generated a tamoxifen-inducible, cardiomyocytespecific leptin receptor knockout mouse to dissect cell-specific actions of leptin signalling in the infarcted heart. Selective disruption of leptin signalling in cardiomyocytes resulted in enhanced ventricular remodelling, accentuated hypertrophy, increased cardiomyocyte apoptosis, more intense inflammation, and impaired glucose metabolism in the infarcted ventricle. These defects were associated with impaired activation of STAT-3 and 5 ′ -AMP-activated protein kinase (AMPK). Rescue experiments demonstrated that the protection afforded by leptin was mediated in part through AMPK signalling. The findings provide important insights into the role of leptinmediated actions following cardiac injury, suggesting potent protective effects against cardiomyocyte apoptosis and hypertrophy via the activation of AMPK. The authors' current observations are in agreement with previous reports showing anti-hypertrophic effects of leptin, 5, 6 but are challenged by in vitro evidence demonstrating prohypertrophic effects of leptin mediated by MAPK/ERK, RhoA/ ROCK, and STAT/JAK pathways 7 
and by in vivo experiments
showing that treatment with a neutralizing leptin receptor antibody attenuated hypertrophy and haemodynamic dysfunction in rats with myocardial infarction. 8 Moreover, exogenous administration of high
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doses of leptin in mice undergoing myocardial infarction protocols resulted in accentuated adverse remodelling. 3 What is the possible explanation for the contradictory reports on the role of leptin in the infarcted heart? Although species-specific effects may account for some of the observed differences, the dose-and context-dependent actions of leptin on the various cell types involved in cardiac remodelling may explain the conflicting observations. Effects of leptin in vivo may be dependent on its local concentration: both complete loss and high-level overexpression of leptin may result in hypertrophy and adverse remodelling following myocardial infarction. More importantly, however, the findings may illustrate the significance of cell-specific actions of leptin signalling on the infarcted heart. Cardiac remodelling following infarction is dependent on the extent of cardiomyocyte injury, 9 but is also greatly influenced by alterations in the inflammatory and reparative response. Extensive evidence suggests that leptin exerts potent pro-inflammatory actions. Hyperleptinaemia is associated with enhanced systemic inflammation 10 and triggers activation of matrixdegrading pathways in the myocardium. 9 In vitro, leptin activates leucocytes via integrin up-regulation 11 and induces expression of matrix metalloproteinases by cultured cardiac fibroblasts. Leptin-induced accentuation of cardiac inflammation and matrix metabolism would be expected to promote dilative remodelling of the infarcted heart. In animals selectively lacking leptin signalling in cardiomyocytes, any protective effects of leptin on cardiomyocyte survival are abrogated, resulting in unopposed pro-inflammatory and matrix-degrading actions on leucocytes and mesenchymal cells. Thus, leptin-mediated effects on leucocytes and fibroblasts may enhance adverse remodelling, inducing accentuation of inflammation and enhanced proteolytic activity, whereas effects on cardiomyocytes may be primarily protective. The meticulous work by McGaffin et al. 4 highlights the complexity and cellular specificity of biological responses and emphasizes the power of conditional manipulation of genes in dissecting the mechanisms involved in cardiac pathophysiological conditions. Figure 1 The cellular effects of leptin. Leptin exerts pleiotropic effects on all cell types involved in cardiac remodelling. F, fibroblast; C, cardiomyocyte; E, endothelium; M, monocyte; Ma, macrophage; N, neutrophil; L, lymphocyte.
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